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Summary: Decreased ferritin and transferrin saturation are associated with protection against 
malaria in African children. Hepcidin, soluble transferrin receptor and hemoglobin concentrations 
are not associated with malaria protection. These findings may reflect differences in parasite iron 
acquisition. 
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Abstract 
Background: It remains unclear whether improving iron status increases malaria risk, and few 
studies have looked at the effect of host iron status on subsequent malaria infection. We therefore 
aimed to determine whether a child’s iron status influences their subsequent risk of malaria 
infection in sub-Saharan Africa. 
Methods: We assayed iron and inflammatory biomarkers from community-based cohorts of 1309 
Kenyan and 1374 Ugandan children aged 0 - 7 years and conducted prospective surveillance for 
episodes of malaria. Poisson regression models were fitted to determine the effect of iron status on 
the incidence rate ratio of malaria using longitudinal data covering a period of 6 months. Models 
were adjusted for age, sex, parasitemia, inflammation and study site. 
Results: At baseline, the prevalence of iron deficiency (ID) was 36.9% and 34.6% in Kenyan and 
Ugandan children, respectively. Iron deficiency anemia (IDA) affected 23.6% of Kenyan and 17.6% of 
Ugandan children. Malaria risk was lower in children with ID (IRR = 0.7; 95% CI: 0.6, 0.8; p<0.001) 
and IDA (IRR = 0.7; 95% CI: 0.6, 0.9; p=0.006). Low transferrin saturation (<10%) was similarly 
associated with lower malaria risk (IRR = 0.8; 95% CI: 0.6, 0.9; p=0.016). However, variation in 
hepcidin, soluble transferrin receptors (sTfR) and hemoglobin / anemia was not associated with 
altered malaria risk.  
Conclusions: ID appears to protect against malaria infection in African children when defined using 
ferritin and transferrin saturation, but not when defined by hepcidin, sTfR or hemoglobin. Further 
research is required to determine causality. 
Keywords: Iron status; Iron deficiency; malaria risk; African children  
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INTRODUCTION 
Iron deficiency (ID) and malaria remain important public health problems in African children [1,2]. 
ID, the most common nutrient deficiency in pre-school African children [3], is associated with poor 
brain development and long-term behavioral and cognitive impairments [4]. Similarly, malaria has 
devastating health effects in African children. In 2015, malaria caused an estimated 292,000 deaths 
in African children under the age of five years [2] and remains a persistent and widespread problem 
in Africa infecting 24% of the population at any one time [5].  
 
The safety of iron supplementation has been a long-standing concern among policy makers and 
clinicians in malaria-endemic areas [6,7]. In these areas, the World Health Organization (WHO) 
recommends iron supplementation in conjunction with effective malaria prevention and treatment 
strategies [8]. However, randomized controlled trials of iron supplementation have reported 
conflicting findings [9,10]. Furthermore, it is unclear whether iron supplementation might be unsafe 
because it improves iron status itself thus resulting in a long-term increase in the risk of malaria. 
 
Few observational studies have investigated the effect of iron status on malaria risk. These studies 
indicate that ID is associated with a reduced risk of both mild and severe Plasmodium falciparum 
malaria in African children [11–14], but have largely used ferritin-based definitions of ID. Little is 
known about whether other indicators of iron status (including hepcidin, hemoglobin, soluble 
transferrin receptors (sTfR), and transferrin saturation (TSAT)) influence malaria risk in humans. In 
mouse models, hepcidin has been shown to play a role in preventing superinfection by depriving the 
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Plasmodium liver stage of iron [15], but studies in children have reported mixed findings [16,17]. 
Two previous studies have reported that hemoglobin concentrations do not influence malaria risk 
[18,19] while in vitro culture indicates otherwise [20]. There are no specific reports of the influence 
of sTfR and TSAT on malaria in humans.  
 
In this study, we aimed to investigate whether a child’s iron status influences their subsequent risk 
of malaria infection in 2683 Kenyan and Ugandan children, thus making this the largest observational 
study on iron status and risk of malaria to date with the most comprehensive range of iron markers. 
 
MATERIALS AND METHODS 
Ethical Approval 
Ethical approval was provided by the Scientific Ethics Review Unit of the Kenya Medical Research 
Institute for the Kenyan cohort and by the Uganda Virus Research Institute and the London School of 
Hygiene & Tropical Medicine for the Ugandan cohort. 
 
Study Population 
This study used data from two African community-based cohorts of children in Kilifi, Kenya and 
Entebbe, Uganda.  
Kenya cohort. This included three community cohorts, Junju, Ngerenya and RTSS. Junju and 
Ngerenya are ongoing rolling cohorts evaluating malaria immunity as described elsewhere [21]. The 
RTSS cohort was the RTS,S/AS01E vaccine trial against malaria that was conducted between 2007 
and 2008 with continued active malaria surveillance for 8 years [22]. Within these cohorts, children 
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are followed-up to a maximum age of 13 years with annual cross-sectional bleeds. The follow-ups 
involved weekly visits to assess for fever and if the temperature was above 37.50C, a malaria blood 
film was taken. Iron biomarkers were measured from a single cross-sectional bleed based on the 
availability of plasma samples archived at -800C. 
 
Uganda cohort. The Entebbe Mother and Baby Study (EMaBS) is a prospective birth cohort study 
that was originally designed as a randomized double-blind placebo-controlled trial 
[ISRCTN32849447] to determine whether anti-helminthic treatment during pregnancy and early 
childhood was associated with differential responses to vaccination or incidence of infections such 
as pneumonia, diarrhea or malaria [23]. Blood samples were collected at birth and at subsequent 
birthdays up to five years of age. Markers of iron status were assayed from a single birthday based 
on the availability of stored samples. The study included longitudinal active surveillance of malaria 
and other infections during fortnightly home visits and quarterly clinic visits.  
 
Longitudinal parasitemia data were obtained from active surveillance during the six months 
following measurement of iron biomarkers. 94% of Kenyan and 90% of Ugandan children were 
followed up for 6 months while the length of follow-up for the remainder ranged from 1-5 months. 
We chose a follow-up period of not more than six months since iron status may change over a longer 
follow-up period. Secondary analyses included a one-year period of follow-up. Clinical malaria data 
included microscopy confirmed density of asexual P. falciparum parasitemia and temperature. 
Genotyping of hemoglobin types was conducted by PCR [24] using DNA extracted by Qiagen DNA 
Blood Mini Kit (Qiagen, West Sussex, United Kingdom). 
 
Measurement of Iron and Inflammatory Biomarkers 
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The assayed biomarkers of iron status included plasma ferritin (Chemiluminescent Microparticle 
Immunoassay (CMI), Abbott Architect, USA), hepcidin (DRG Hepcidin 25 [bioactive] HS ELISA Kit, DRG 
Diagnostics), sTfR (Human sTfR ELISA, BioVendor, CZ), iron (MULTIGENT iron calorimetric assay, 
Abbott Architect, USA), transferrin (CMI, Abbott Architect, USA), and hemoglobin (Medonic CA 530 
Hemoglobinometer). Since biomarkers of iron are influenced by inflammation, C-reactive protein 
(CRP) (MULTIGENT CRP Vario assay, Abbott Architect, USA) was assayed to adjust for inflammation 
[25]. 
 
Definitions 
Two definitions of ID were used: 1) based on low ferritin defined as plasma ferritin < 12µg/L or < 
30µg/L in the presence of inflammation (CRP > 5mg/L) in children < 5 years or < 15µg/L in children  
5 years; [25] and 2) TSAT < 10% (calculated as iron in µmol/L / (transferrin in g/L x 25.1) x 100) [26]. 
TSAT was calculated in Kenya only because Ugandan plasma samples were stored in 
ethylenediaminetetraacetic acid (EDTA), which chelates iron.  We did not define ID by hepcidin or 
sTfR since there are no internationally established cut-offs. Anemia was defined as hemoglobin < 
11g/dL in children aged 0 to 4 years or hemoglobin < 11.5 g/dL in children above 4 years while iron 
deficiency anemia (IDA)  was defined as low ferritin and anemia [27]. A malaria episode was defined 
as parasitemia and temperature > 37.50C. All malaria episodes occurring during the follow-up period 
were included except those occurring within 14 days of an initial presentation, which were regarded 
as recrudescence. 
 
Statistical Analyses 
All analyses were conducted using STATA 13.0 (StataCorp., College Station, TX). Iron biomarkers 
(except hemoglobin) were loge-transformed to normalize their distributions. Geometric means of 
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iron biomarkers and proportions of ID and anemia were computed. Two-tailed Student’s t-tests 
were used to test for difference in means between groups. Poisson regression models of counts of 
malaria episodes were fitted as predicted by iron status (ID / anemia / individual iron biomarkers) 
and were adjusted for age, sex, parasitemia, inflammation and study site. Difference in individual 
length of follow-up was accounted for in the model by including the length of follow-up as 
“exposure” in the model. We accounted for multiple episodes using robust cluster variance 
estimation which takes into account correlations between multiple events. Secondary analyses 
involved excluding children with parasitemia or inflammation at baseline to mitigate the effects of 
concurrent infection on iron status [28]. We used Cox proportional hazards analyses to evaluate the 
temporal effect of iron status on malaria risk. A p-value of < 0.05 was considered significant.  
 
We searched the databases PubMed and Google Scholar with search terms that included “ID OR 
ferritin OR hepcidin OR sTfR OR TSAT OR hemoglobin OR anemia AND malaria children”. We found 
four longitudinal studies investigating the effect of ID on malaria risk. A meta-analysis of the current 
study and previous longitudinal studies investigating the relationship between ID and malaria risk 
was performed using the “metan” command in STATA. 
 
RESULTS 
Baseline Characteristics of Study Population 
A total of 1309 Kenyan and 1374 Ugandan children aged between 0 - 7 years and 1 - 5 years 
respectively were included in the analyses. Table 1 shows the characteristics of study participants. At 
baseline, the prevalence of ID and IDA were 36.9% and 23.6% in Kenyan and 34.6% and 17.6% in 
Ugandan children respectively. The prevalence of ID based on TSAT (measured in Kenya only) was 
52.4%. The prevalence of malaria parasitemia was higher in Kenyan (20.1%) compared to Ugandan 
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children (6.7%). During the six-month follow-up, 31.1% of Kenyan and 14.3% of Ugandan children 
experienced at least one episode of malaria infection. Malaria incidence rate per child-year of 
follow-up was 0.6 in Kenya and 0.3 in Uganda.  
 
Higher Ferritin Concentrations and TSAT are Positively Associated with Malaria Infection 
Concentrations of ferritin and TSAT, but not other iron markers, were higher in children that 
subsequently developed a malaria episode (Figure 1A). Similarly, a unit increase in log ferritin was 
associated with an increased incidence rate ratio for malaria overall (IRR = 1.3; 95% CI: 1.2, 1.4; p < 
0.001) and in each cohort individually (Figure 1B). A unit increase in log TSAT was also associated 
with a 20% increased risk of malaria in Kenyan children (IRR = 1.2; 95%CI: 1.05, 1.4); p = 0.009). 
However, hepcidin, sTfR and hemoglobin concentrations were not associated with subsequent risk 
of malaria (Figure 1B).  
 
ID Defined Using Ferritin or TSAT Protects Against Malaria Risk 
ID defined by low ferritin concentrations and IDA were associated with a 30% reduction in the 
incidence of malaria infection (IRR = 0.7; 95% CI: 0.6, 0.8; p < 0.001 and IRR = 0.7; 95% CI: 0.6, 0.9; p 
= 0.006, respectively). These findings were consistent for the individual cohorts (Table 2). Likewise, 
ID defined by low TSAT reduced the risk of malaria in Kenyan children (IRR = 0.8; 95% CI: 0.6, 0.9; p = 
0.016). However, anemia itself was not significantly associated with variation in malaria risk (Table 
2).  
 
In Cox proportional hazards models, ID defined by low ferritin, ID defined by low TSAT, and IDA were 
associated with 40%, 20% and 30% reduced risk of malaria respectively (Figure 2A-C) for the six 
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months of follow-up compared to iron replete children. However, anemia was not associated with 
malaria risk (Figure 2D and Supplementary Table 1). 
We observed similar results regardless of whether the follow-up period was extended to one year, 
the children had malaria parasitemia or inflammation at baseline, age, or following adjustment for 
sickle cell trait (Supplementary Figures 1-5). 
 
A meta-analysis of observational studies examining the influence of ID on malaria risk is shown in 
Figure 3. All the studies report that ID, using a ferritin-based definition, protects against malaria 
infection, despite differences in study site, length of follow-up, and definition of ID (Supplementary 
Table 2). The overall estimate indicates that ID is associated with a 34% lower risk of malaria 
infection. We report the largest study to date. 
 
DISCUSSION 
In this study, we report an observational analysis of the influence of iron status on subsequent 
malaria risk in 2683 Kenyan and Ugandan children. We found that ID, defined using either ferritin or 
TSAT, and IDA were associated with a lower risk of subsequent malaria infection. However, anemia 
(or hemoglobin concentrations), hepcidin and sTfR were not significantly associated with variation in 
malaria risk. 
 
Consistent with our findings, previous observational studies have reported that ID based on low 
ferritin concentrations confers protection against malaria infection in African children [11–14]. 
Nyakeriga et al reported a 30% reduction in clinical malaria during a six month follow-up of Kenyan 
children aged 8 months to 8 years [11]. Similarly, studies in Malawi (aged 6 - 60 months with one 
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year of follow-up) [12] and Tanzania (birth to 3 years follow-up) [13] reported reduced malaria risk 
of 45% and 23% respectively. Recently, a study in Zambian children aged 4 - 8 years followed-up for 
six months reported an increased risk of malaria in children with high ferritin concentrations [14]. 
These estimates are similar to our finding of a 30% reduction in malaria risk in iron deficient children 
(0 - 7 years).  
 
We further found that ID defined by TSAT was associated with a 20% reduction in the subsequent 
risk of malaria and TSAT was positively associated with malaria incidence. Using a combination of 
low TSAT and low ferritin, Nyakeriga et al reported a 30% reduction in clinical malaria among iron 
deficient children [11]. In support of our findings, P. falciparum has been demonstrated to obtain 
iron from transferrin using in vitro parasite culture [29]. Furthermore, Clark et al demonstrated that 
parasitized red blood cells utilize serum iron [30]. These studies indicate that increasing bioavailable 
transferrin-bound iron may predispose an individual to increased risk of malaria. And indeed, we 
show that higher TSAT may increase malaria risk in children. 
 
So how might ID protect against malaria infection? In in vitro parasite cultures iron deficient human 
erythrocytes are poorly infected by P. falciparum compared to those that are iron replete and this 
protective effect is reversed by iron supplementation [31].  In mouse models, Matsuzaki-Moriya et 
al. showed that during ID, macrophages cleared parasitized erythrocytes more efficiently suggesting 
that either erythrocytes produced under iron deficient conditions are easily phagocytized by 
macrophages or that there is an enhancement of macrophage function during ID [32]. Furthermore, 
ID has also been shown to up-regulate nitric oxide which has anti-parasitic properties against 
Plasmodium [33]. Another possible explanation is that during ID, zinc is incorporated in place of iron 
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during heme synthesis leading to formation of zinc protoporphyrin that in turn is thought to inhibit 
formation of hemozoin (the parasite survival pigment) in a manner similar to quinolines [34]. 
 
We further report that anemia (or hemoglobin concentration) does not influence subsequent 
malaria risk. Similar observations have been reported by two previous studies. A recent longitudinal 
study in Papua New Guinean infants aged 3 months and followed-up for one year reported a non-
significant association between lower hemoglobin concentrations and subsequent malaria infection 
[18]. A similar observation was made by Ghosh et al in Indian children [19]. Indeed, both studies and 
ours report that anemic children have a non-significant increase in malaria risk rather than 
protection from malaria. In contrast, Goheen et al reported that anemia was associated with 
decreased in vitro growth rate of P. falciparum [20]. However, it is possible that in vitro parasite 
growth rate might not mimic direct malaria susceptibility for children. Moreover, hemoglobin has 
low sensitivity and specificity in determining body iron status due to the overlap of values in iron 
deficient and replete individuals [35] and the multiple overlapping causes of low hemoglobin 
concentrations in African children [36]. It further remains unclear whether the malaria parasite 
utilizes heme iron in hemoglobin or has other sources and mechanisms of iron acquisition. There are 
suggestions that the parasite may utilize storage iron since bioavailable iron content increases in 
parasitized red blood cells as the parasite develops from ring stage to schizont [30].  
 
We further hypothesized that raised hepcidin concentrations may reduce malaria risk through 
sequestering iron within macrophages and enterocytes [37], thereby starving liver-stage 
Plasmodium [15]. Since the parasite requires iron for growth, it has been suggested that withholding 
iron from hepatocytes inhibits the development of malaria [15]. Furthermore, high cord blood 
hepcidin has been associated with decreased risk of clinical malaria although not parasitemia or 
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severe malaria in Tanzanian infants [17]. However, in agreement with our study in an independent 
cohort of Kenyan children [16], we found no association between hepcidin concentrations and 
clinical malaria episodes. Differences in age or environmental factors may account for the different 
findings. Moreover, the high prevalence of ID, which is normally associated with decreased hepcidin, 
and reduces the risk of malaria in our participants, may counter a possible protective role of 
hepcidin. 
 
Our data indicate that a child’s erythropoietic drive (as measured by sTfR) does not influence their 
subsequent risk of malaria infection. The expression of sTfR increases with both ID and expanded 
erythropoiesis (with the latter being more influential) [38], factors that might have opposing effects 
on malaria risk. For example, increased erythropoiesis may increase the risk of malaria since 
Plasmodium parasites preferentially infect young red blood cells [39], whereas ID may be protective. 
These opposing effects could explain why sTfR concentrations were not associated with malaria risk 
in our study. It is also known that malaria itself causes increased sTfR concentrations [38,40].   
 
A major challenge in this study is that iron biomarkers are themselves influenced by infections and 
inflammatory processes which may confound the effect of iron status on malaria infection [28]. To 
mitigate the potential confounding effects of infection on iron biomarkers, we excluded children 
with inflammation or malaria parasitemia at the time of iron measurement in secondary analyses 
and observed similar results (Supplementary Figure 2). Additionally, other potential confounders 
such as age, sex, length of follow-up and study site were adjusted for in regression models. 
Limitations of the study were lack of TSAT concentrations in Ugandan children and that only febrile 
malaria was included for the malaria episodes. Strengths of our study included its large size (n=2,683 
children) across two study sites and that we used multiple iron biomarkers in order to determine 
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their individual effects on malaria risk making it the largest and most definitive observational study 
to address the question of iron status and risk of malaria infection.  
 
Our findings, in agreement with other studies, suggest that ID protects children against malaria 
infection and thus that improving iron status may predispose African children to infection. 
Interestingly, of the iron biomarkers, only higher concentrations of ferritin and TSAT were predictive 
of increased rates of subsequent malaria, perhaps reflecting differences in their relationship to 
parasite mechanisms of iron acquisition.  Although WHO recommends iron supplementation coupled 
with malaria treatment and prevention strategies in malaria endemic areas [8], these strategies 
remain difficult to implement. Thus, it is important to establish whether improved iron status 
increases malaria risk since this would necessitate long-term malaria prevention and treatment 
programs. However, our findings and that of other studies do not necessarily imply causality since 
observational studies may be subject to confounding and reverse causation, for example, prior 
malaria exposure might lead to both ID and the acquisition of protective immunity against malaria, 
while malaria itself increases ferritin levels. Since ID prevents children from reaching their 
developmental potential it is important to establish causality in the iron-malaria relationship. Thus, 
these data warrant further large-scale studies, including studies which utilize genetic variants 
associated with iron status to infer causality (Mendelian randomization), and prospective 
interventional trials.  
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Table 1: Baseline characteristics of study participants 
 Kenya, n=1309 Uganda, n=1374 
Mean age in years (range) 2.3 (0.0, 7.1) 2.3 (1.0, 5.1) 
Sex, n/total (%)   
Males 668/1309 (51.0) 696/1374 (51.7) 
Females 641/1309 (49.0) 678/1374 (49.3) 
Malaria parasitemia, n/total (%) 261/1296 (20.1) 92/1371 (6.7) 
Inflammation, n/total (%)a 334/1264 (26.4) 316/1337 (23.6) 
Iron deficiency, n/total (%)b   
      Low ferritin 457/1237 (36.9) 438/1267 (34.6) 
      TSAT<10% 637/1215 (52.4) n/a 
                                                          
gmean, geometric mean; sd, standard deviation; sTfR, soluble transferrin receptors; TSAT, transferrin 
saturation. 
a
 Inflammation was defined as C-reactive protein > 5mg/L 
b Iron deficiency was defined using two definitions: 1) Low ferritin defined as plasma ferritin < 
12µg/L or < 30µg/L in the presence of inflammation in children < 5 years or  < 15µg/L in children  5 
years; and 2) Transferrin saturation < 10% (available in 1215 Kenyan children only and not available 
(n/a) in Uganda).  
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Anemia, n/total (%)a 526/765 (68.8) 533/1312 (40.6) 
Iron deficiency anemia, n/total (%)b 172/729 (23.6) 213/1209 (17.6) 
Sickle cell trait, n (%) 157/1057 (14.9) 224/1355 (16.5) 
Ferritin, n (gmean±sd) in µg/L 1237 (20.8±3.0) 1267 (20.8±2.9) 
Hepcidin, n (gmean±sd) in µg/L 1202 (5.6±3.6) 1333 (6.8±3.3) 
sTfR, n (gmean±sd) in mg/L 1296 (17.8±1.5) 1343 (6.7±2.0) 
Hemoglobin, n (gmean±sd) in g/dL 765 (10.1±1.2) 1312 (11.0±1.1) 
Transferrin saturation, n (gmean±sd) in % 1215 (9.3±2.2) n/a 
                                                          
a Anemia was defined as hemoglobin < 11g/dL in children aged 0 to 4 years or hemoglobin < 11.5 
g/dL in children above 4 years. The range of hemoglobin was 5.1-14.7 in Kenya and 5.4-18.5 in 
Uganda while interquartile range (IQR) was 9.4-11.3 in Kenya and 10.3-12.1 in Uganda. Only 33 
(1.6%) had severe anemia (Hb<7g/dL in under 5 years or <8g/dL in over 5 years old). 
b Iron deficiency anemia was defined as low ferritin and anemia. 
Malaria incidence rate per child-year of follow-up was 0.6 in Kenya and 0.3 in Uganda. 
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Table 2: Incidence of malaria by iron status and anemia 
  Kilifi, Kenya  Entebbe, Uganda Overall 
 
No. No. of episodes Incidence 
IRR  
(95% CI) 
p  No. No. of episodes Incidence 
IRR  
(95% CI) 
p  No. No. of episodes Incidence 
IRR  
(95% CI) 
p  
No ID (iron replete) 780 286 0.8 1 
 
829 140 0.3 1 
 
1609 426 0.6 1 
 
ID (low ferritin)a 457 93 0.4 0.8 (0.6, 0.9) 0.018 438 45 0.2 0.5 (0.4, 0.7) <0.001 895 138 0.3 0.7 (0.6, 0.8) <0.001 
No ID (TSAT 10%) 578 224 0.8 1  n/a n/a n/a n/a n/a 578 224 0.8 1  
ID (TSAT <10%)b 637 159 0.5 0.8 (0.6, 0.9) 0.016 n/a n/a n/a n/a n/a 637 159 0.5 0.8 (0.6, 0.9) 0.016 
No anemia 239 97 0.8 1  779 93 0.2 1  1018 190 0.4 1  
Anemiac 526 219 0.9 1.0 (0.8, 1.2) 0.774 533 93 0.4 1.2 (0.9, 1.6) 0.156 1059 312 0.6 1.1 (0.9, 1.3) 0.168 
No IDA  557 257 1.0 1 
 
996 154 0.3 1 
 
1553 411 0.5 1 
 
                                                          
ID, iron deficiency; IDA, iron deficiency anemia; TSAT, transferrin saturation 
a
 Iron deficiency (low ferritin) was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of inflammation (CRP > 5mg/L) in children < 5 years or  < 15µg/L in children  5 years 
otherwise iron replete. 
b
 Transferrin saturation data were available in 1215 Kenyan children. Not available (n/a) for Uganda. 
c
 Anemia was defined as hemoglobin < 11g/dL in children aged 0 to 4 years or hemoglobin < 11.5 g/dL in children above 4 years. 
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IDAa 172 47 0.6 0.8 (0.6, 1.1) 0.269 213 23 0.2 0.5 (0.3, 0.7) <0.001 385 70 0.4 0.7 (0.6, 0.9) 0.006 
                                                          
a
 Iron deficiency anemia was defined as low ferritin and anemia.  
Poisson regression models were adjusted for age, sex, parasitemia, inflammation, length of follow-up, and study site. Maximum length of follow-up was 6 months. IRR=Incidence rate ratio. 
Incidence defined as number of malaria episodes per child-year of follow-up. The number of episodes ranged from 0-5 in Kenya and 0-6 in Uganda. 101 Kenyan and 45 Ugandan children had 
multiple episodes. 
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Figure Legends 
 
Figure 1: The effect of iron status on subsequent malaria A) Scatter plots of iron 
biomarkers stratified by no subsequent malaria or one or more subsequent malaria episodes. 
Horizontal red line indicates mean while vertical line indicates standard deviation. P value 
was derived from Poisson regression model. B) Adjusted incidence rate ratios for the effect 
of iron biomarkers on subsequent malaria episodes. Green indicates overall, red Kenya and 
blue Uganda. Labels indicate incidence rate ratio and 95% confidence intervals. Poisson 
regression models were adjusted for age, sex, parasitemia, inflammation, length of follow-up 
and study site. Maximum length of follow-up was 6 months. sTfR, soluble transferrin 
receptor; TSAT, transferrin saturation.  
 
Figure 2: Kaplan-Meier curves of time to first malaria episode according to A) iron deficiency (ID) 
defined by low ferritin, (B) ID defined by transferrin saturation (TSAT < 10%), (C) iron deficiency 
anemia (IDA), and (D) anemia. P values were derived from log-rank tests for equality of survivor 
functions. 
 
Figure 3: Meta-analysis of observational studies examining the relationship between iron deficiency 
(ID) and malaria risk. Study-specific estimates and their relative contribution (percentage weight and 
sample size) to overall estimates are shown. Definitions of ID  varied by study: Nyakeriga et al 2004, 
ferritin < 12µg/L plus TSAT < 10%; Jonker et al 2012, ferritin < 30µg/L; Gwamaka et al 2012, Ferritin < 
30µg/L if CRP < 8.2mg/L or ferritin < 70µg/L if CRP > 8.2mg/L; Barffour et al 2017, ferritin < 12µg/L in 
children < 5 years or <15µg/L in children  5 years; and current study, ferritin < 12µg/L or  < 30µg/L if 
CRP > 5mg/L in children < 5 years or < 15µg/L in children  5 years. 
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Figure 3. 
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